OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-11-01
DOI
10.3389/fimmu.2019.02578
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
- (2019) Yang Yang et al. Cell Death & Disease
- IL-1β enables CNS access to CCR2himonocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells
- (2018) Alexandre Paré et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
- (2018) Carlo Marchetti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases
- (2018) Bo-Zong Shao et al. Frontiers in Molecular Neuroscience
- Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain
- (2017) Nemat Khan et al. INFLAMMOPHARMACOLOGY
- Further understanding of the immunopathology of multiple sclerosis: impact on future treatments
- (2016) Vikram Bhise et al. Expert Review of Clinical Immunology
- Myeloid cell transmigration across the CNS vasculature triggers IL-1β–driven neuroinflammation during autoimmune encephalomyelitis in mice
- (2016) Sébastien A. Lévesque et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A basic overview of multiple sclerosis immunopathology
- (2015) N. Grigoriadis et al. EUROPEAN JOURNAL OF NEUROLOGY
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
- (2015) Rebecca C Coll et al. NATURE MEDICINE
- The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients
- (2014) Masoumeh Heidary et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53
- (2014) Silvia Rossi et al. Molecular Neurodegeneration
- Inflammasomes in health and disease
- (2012) Till Strowig et al. NATURE
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
- (2012) Charles A. Dinarello et al. NATURE REVIEWS DRUG DISCOVERY
- The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond
- (2011) Cristina Conforti-Andreoni et al. Cellular & Molecular Immunology
- The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
- (2011) P. Menu et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The Immunopathophysiology of Multiple Sclerosis
- (2011) Gregory F. Wu et al. NEUROLOGIC CLINICS
- NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses
- (2010) D. Gris et al. JOURNAL OF IMMUNOLOGY
- Critical Regulation of Early Th17 Cell Differentiation by Interleukin-1 Signaling
- (2009) Yeonseok Chung et al. IMMUNITY
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis
- (2009) Luigi Franchi et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now